2.22k followers • 19 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endologix (ELGX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
The Audubon, Pennsylvania-based company said it had net income of 36 cents per share. Earnings, adjusted for one-time gains and costs, came to 43 cents per share. The results topped Wall Street expectations. ...
Globus Medical (GMED) delivered earnings and revenue surprises of 7.50% and 0.22%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, Intuitive Surgical (ISRG) closed at $549.87, marking a +0.04% move from the previous day.
About 20 years ago, a medical device startup called Intuitive Surgical debutedthe da Vinci robot and changed surgical practices in operating rooms acrossthe United States
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018, a YoY rise of
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Expense projections for fiscal 2019 In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted SG&A (selling, general, and
NuVasive (NUVA) delivered earnings and revenue surprises of 9.52% and 0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had net income of 23 cents. Earnings, adjusted for amortization costs and non-recurring costs, came to 69 cents per share. The results surpassed ...